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Abstract
Compounds derived from biologic sources, or biologicals, are increasingly utilized as therapeutic
agents in malignancy. Development of anti-cancer targeted therapies from biologics is increasingly
being utilized. Cetuximab, a chimeric monoclonal antibody, is one such anti-cancer targeted
therapeutic that has shown efficacy in quelling the rate of patient decline in colorectal, head/neck,
and non-small cell lung cancer. However, due to the relatively recent addition of biologic
compounds to the therapeutic arsenal, information related to adverse reactions is less well known
than those seen in traditional chemotherapeutics. Dermatologic reactions have been demonstrated
as the most frequent side effect cited during cetuximab therapy for malignancy; however, other
effects may lead to greater morbidity. In general, pulmonary complications of therapeutics can lead
to significant morbidity and mortality. The purpose of this review is to compile the various
pulmonary side effects seen in patients treated with cetuximab for various malignancies, and to
compare the incidence of these adverse reactions to standard therapies.
Background
Biological Therapies
Biologic therapies, or biologicals, are those produced or
extracted from a biological source. Based upon the specific
agent, biologicals have a myriad of activities and have
been used to modulate immunity, increase blood cell pro-
duction, inhibit tumor growth, and other effects [1]. Over
the last 5 years, more than 20% of the compounds
approved by United States regulatory authorities were bio-
logics [2]. Despite this explosion in the availability of bio-
logicals, surprisingly limited data exists regarding adverse
events associated with their use.
Because these compounds are derived from biologic
sources, they have the potential for significant immune
activation. Although extensively reported in clinical trials,
adverse events are rarely compiled in the medical litera-
ture. Giezen and coauthors examined adverse event
reporting post-approval for biologicals and suggested that
there was a need for increasing awareness to certain risks
associated with the therapeutic use of biologicals [2].
Cetuximab (Erbitux®)
One such biologic therapy used in the treatment of malig-
nancy is cetuximab (Erbitux®, ImClone, Branchburg, NJ).
Cetuximab is a chimeric monoclonal antibody with
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(EGFR). Cetuximab has been extensively studied and
approved [3] for the treatment of metastatic colorectal
cancer (MCRC) and squamous cell head/neck cancers
(SCCHN), and growing data supports its use in the treat-
ment of other malignancies including non-small cell lung
cancer (NSCLC). Cetuximab has been evaluated in the set-
ting of combination therapy or as a single agent in con-
ventional therapy failures. Moreover, cetuximab has been
studied for the treatment of various other malignancies
including breast cancer and ovarian cancer, hepatocellular
cancer, pancreatic cancer, and others.
Through binding to the extracellular domain of EGFR,
cetuximab interrupts the signaling cascade resulting in
inhibition of cell growth, induction of apoptosis, and
decreased matrix metalloproteinase and vascular
endothelial growth factor production [3]. EGFR, a mem-
ber of the ErbB-1 family of receptors, is closely related
structurally to other tyrosine kinase receptors including
HER2/c-neu (ErbB-2), Her 3 (ErbB-3), and Her 4 (ErbB-
4)[4]. Over expression or increased activity of EGFR as
seen in some mutations can result malignancy [4].
Cetuximab efficacy has been studied as a single agent as
well as in combination with other chemotherapeutic
modalities. A randomized controlled clinical trial with
329 patients was conducted using cetuximab plus irinote-
can or cetuximab alone in treatment of EGFR-expressing
MCRC [3]. Cetuximab was shown to lengthen the time to
disease progression by 4.2 months in the monotherapy
arm and 5.7 months in combination arm. In patients with
EGFR-positive NSCLC a phase II study by Rosell showed
that combination cisplatin/vinorelbine plus cetuximab
resulted in an overall response rate of 32%, compared to
20% with cisplatin/vinorelbine alone [5]. The continuing
research of cetuximab is helping to determine which pop-
ulations of patient will benefit most from Anti-EGFR ther-
apy. Currently most evidence points towards the use of
cetuximab in combination with other chemotherapeutic
regimens as the best option for treatment in EGFR positive
tumors.
Epidermal growth factor receptors are ubiquitous, thus
potential for exuberant reactions including adverse events
is high. Moreover, due to the diverse tissues expressing
EGRF, adverse reactions manifest in many ways. Although
dermatologic reactions represent the vast majority of
adverse events, occurring in between 3090% of patients
depending on the severity and study examined [6,7],
many other side effects occur with cetuximab therapy.
Other adverse events increased above control groups
included gastrointestinal complaints (1959%) and head-
ache (19%) [3]. Cextuximab infusion reactions took place
in between 15 and 20% of subjects [3].
There have only been rare reports of pulmonary side
effects with cetuximab. Interstitial lung disease was
reported in 4 of 1,570 (0.25%) patients with advanced
colorectal cancer [3]. There have also been reports of inter-
stitial pneumonitis with non-cardiogenic pulmonary
edema [8]. The use of cetuximab in combination regi-
mens potentially clouds side effect profiles.
Pulmonary complications in the setting of chemotherapy
lead to increased morbidity and severe reactions are asso-
ciated with mortality. Cetuximab, like many other cancer
therapies, has been demonstrated to cause a wide range of
respiratory effects from mild dyspnea to a fatality due
adverse pulmonary events. The purpose of this investiga-
tion is to compile a comprehensive list of pulmonary
adverse events in the setting of therapy with cetuximab
published in the literature in order to better characterize
the true incidence of these reactions. A better understand-
ing of the prevalence may help the clinician respond
appropriately to specific symptom changes during the
therapeutic window with a hope of improving patient
care.
Methods
We performed a MEDLINE™ search of the English lan-
guage literature using the search terms: "cetuximab" or
"Erbitux" with limits to include only human studies to
develop a complete index of trials or reports. Inclusion cri-
teria were clinical trials, meta-analyses, or randomized
controlled trials that included the search terms and cited
adverse events. The reference lists from each of these man-
uscripts were scanned to isolate articles not obtained in
the MEDLINE® search to complete our database. Studies
were excluded if they did not list adverse events.
Data extracted from each report included number of
patients, controls, type of cancer, coincident chemother-
apy administration, and information regarding pulmo-
nary complications. Pulmonary complications included
the incidence of symptoms related to the respiratory sys-
tem including dyspnea, cough, wheezing, pneumonia,
hypoxemia, respiratory insufficiency/failure, pulmonary
embolus, pleural effusion, and non-specific respiratory
disorders. Incidences of these pulmonary complications
were obtained from each study's control group if available
and compared between the patients that received cetuxi-
mab and those who did not. Infusion reactions were
treated as a separate complication to cetuximab and were
not included in this analysis, although in many individu-
als, symptoms of shortness of breath and chest tightness
may be encompassed by this type of reaction [9].
Data Analysis and Statistics
Data is presented as the number of patients and percent-
age receiving the study medication as well as means (±Page 2 of 8
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adverse reactions.
Number Ref: Author Year Study Type Cancer Type Combined Agents Pulmonary Reactions
1 51 Vermorken 2008 Phase II SCCHN platinum dyspnea, Pneumonia
2 29 Koo 2007 Phase II Colorectal FOLFIRI, irinotecan dyspnea
3 8 Leard 2007 case SCCHN DAD
4 16 Burtness 2005 Phase III SCCHN cisplatin dyspnea, hypoxia
5 15 Bourhis 2006 Phase I/II SCCHN cisplatin, carboplatin/5-
fluorouracil
respiratory symptoms
6 12 Baselga 2005 Phase II SCCHN platinum respiratory disorder
7 50 Vermorken 2007 review SCCHN cisplatinum, carboplatin dyspnea, infusion rxn
8 20 Cunningham 2004 Prospective Colorectal irinotecan dyspnea
9 53 Xiong 2004 Phase II Pancreatic gemcitabine Pneumonia, Sepsis, PE, Pulm 
Insufficeincy
10 19 Chan 2005 Phase II Nasopharyngeal carboplatin Pleural Effusion, Dyspnea, 
Pneumonia
11 40 Robert 2005 Phase I/II NSCLC gemcitibine, carboplatin Pulmonary Embolism
12 23 Hanna 2006 Phase II NSCLC Dyspnea
13 54 Zhu 2007 Phase II HCC Cough
14 31 Machiels 2007 Phase I/II Colorectal capecitabine, ExBR Pulmonary Embolism, Pulm 
Infetion
15 13 Bonner 2006 RCT SCCHN ExBR cough, increased sputum
16 32 Martin-Martorell 2008 Phase II Colorectal irinotecan none
17 28 Konner 2008 Phase II Ovarian carboplatin, paclitaxel Dyspnea
18 56 Hughes 2008 Phase I/II NSCLC platinum, ExBR 64 Gy dyspnea, pneumonitis, pulm 
embolism, pneumonia
19 11 Asnacios 2008 Phase II HCC oxaliplatin, gemcitabine none
20 18 Cascinu 2008 Phase II Pancreatic cisplatin, gemcitabine none
21 35 Paule 2007 Phase II Cholangiocarcinoma oxaliplatin, gemcitabine none
22 47 Tabernero 2007 Phase II Colorectal oxaliplatin, 5-fluorouracil Dyspnea
23 27 Jonker 2007 rescue Colorectal prev-oxal, irinotecan, 
flouropyrimidine
dyspnea
24 42 Safran 2008 phase II Espohageal carboplatin, paclitaxel, ExBR Pneumonia
25 26 Ibrahim 2007 phase II Colorectal oxaliplatin, irinotecan none
26 38 Pinto 2007 phase II Gastric/GE irinotecan, 5-fluorouracil none
27 46 Souglakos 2007 phase II Colorectal oxaliplatin, capecitabine none
28 30 Lenz 2006 phase II Colorectal prev-oxaloplatin, irinotecan, 
flouropyrimidine
none
29 25 Hofheinz 2006 phase I Colorectal capecitabine, irinotecan, 
ExBR
none
30 24 Herbst 2005 phase II SCCHN cisplatin none
31 43 Saltz 2004 phase II Colorectal previous irinotecan none
32 52 Vincenzi 2006 phase II Colorectal irinotecan none
33 37 Pfister 2006 phase II SCCHN cisplatin, ExBR pneumonia
34 39 Robert 2001 phase I SCCHN ExBR none
35 48 Thienelt 2005 Phase I/II NSCLC carboplatin, paclitaxel pulmonary embolism
36 34 Neyns 2008 Phase II Colorectal oxaloplatin or irinotecan Interstitial pneumonitis
37 10 Arnold 2008 Phase Ib/II Colorectal oxaliplatin, 5-fluorouracil None
38 45 Sobrero 2008 Phase III Colorectal irinotecan None
39 44 Secord 2008 Phase II Ovarian carboplatin Pulmonary rxn
40 14 Borner 2008 Phase II Colorectal oxaliplatin, capecitabine none
41 21 Gamucci 2008 Phase II Colorectal irinotecan none




43 17 Butts 2007 Phase II NSCLC gemcitabine, Cisplatin, 
Carboplatin
dyspnea, Cough, Pneumonia
44 36 Pessino 2008 Phase II Colorectal none none
45 5 Rosell 2008 Phase II NSCLC cisplatin, vinorelbine resp symptoms
46 41 Rodel 2008 Phase I/II Colorectal capecitabine, ExBR, 
Oxaliplatin
none
47 33 Modi 2006 Phase I Breast paclitaxel none
48 22 Gebbia 2006 retrospect rev Colorectal irinotecan nonePage 3 of 8
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were made using Chi-Square or students t-test where
appropriate, and statistical significance was set as p < 0.05.
Results
Using our search criteria defined above, a total of 245 arti-
cles were obtained for review. From this complete group,
192 articles were excluded for not meeting inclusion crite-
ria. Reasons for exclusion were: non-pulmonary focus
(dermatologic side effects), duplicate patient populations,
case reports not relevant to pulmonary side effects, focus
on pharmacokinetics, omission of side effects, or non-
cetuximab trials. A total of 53 studies (Table 1) met inclu-
sion and were included in the analysis [5,8,10-60].
The majority of clinical trials focused on the treatment of
colorectal cancers with head/neck, lung, and hepatobil-
iary or pancreatic making up the next largest groups
(Table 1). Similarly, most of the studies examined were
completed as Phase I or II trials with the focus on refrac-
tory and metastatic disease (Table 2).
A total of 7,411 patients were included in the 53 studies
reviewed including 4,436 (59.8%) patients who received
cetuximab either alone or in conjunction with other
chemotherapeutic medications or radiation therapy.
2,596 (41.4%) patients were in the control groups from
these investigations who received the same chemotherapy
or radiation therapy without cetuximab (Table 3).
Pulmonary Reactions
A total of 459 patients (10.3%) in the cetuximab group
had adverse pulmonary reactions compared to 221
(8.5%) who received standard, non-cetuximab therapy (p
< 0.02). Studies focusing on colorectal cancer, lung can-
cer, and head-neck cancer had sufficient numbers in both
the cetuximab and control groups to compare pulmonary
complications; however, hepatobiliary, pancreatic, breast,
ovarian, and cutaneous cancer studies lacked adequate
numbers of control patients to compare these complica-
tions.
Colorectal cancer studies demonstrate a low rate of pul-
monary complications overall with 3.41% incidence in
the cetuximab group versus 2.56% in the control patients
(p = NS). The most common side effect was dyspnea in
these studies making up more than 90% of the adverse
reactions.
Pulmonary adverse events were much more common, as
would be expected in NSCLC trials with an incidence of
18.7% in the cetuximab group versus 12.2% in the control
arms (p < 0.001). Similarly, dyspnea made up the major-
ity of pulmonary adverse events (13.2% vs 9.2%, p < 0.02)
with other significant differences occurring in the inci-
dence of pneumonitis (1.1% versus 0.0%, p < 0.001)
being worse in the cetuximab groups.
For head-neck cancer studies, the overall rates of pulmo-
nary complications were similar between the cetuximab
and control groups (17.9% versus 20.1%, p = NS), but
favored the cetuximab group. Dyspnea was more com-
mon in the cetuximab group (8.7%) than the control
group (5%, p < 0.02) in Head and Neck Cancer Trials.
Conversely, there were fewer patients with increased spu-
tum production (3.0% versus 6.6%, p < 0.01) and cough
(4.5% versus 7.8%, p < 0.01) in the control group com-
pared to the cetuximab group. From all studies, the differ-
ence in other pulmonary adverse events appears to be
similar (Table 4).
Discussion
Overall, cetuximab seems to increase the incidence of
adverse pulmonary reactions compared to controls,
although the absolute difference between groups is low
(<2%). The severity of the pulmonary complications was
not well described in most of the included studies, but did
not increase mortality rates. To the contrary, if survival
benefits were not demonstrated, almost universally, there
was an increase in progression free survival or stability of
malignancy in these trials. To this point, the difference
between statistical significance and clinical significance
should also be examined in relation to the pulmonary
reactions. For all clinical trials except NSCLC, the differ-
ences in pulmonary adverse events between those treated
with and without cetuximab are small. Dyspnea and
cough, though increased in the cetuximab groups, did not
appear to limit the therapeutic course.
The observation of increased pulmonary adverse events in
patients with NSCLC when compared to controls was
striking. Again, most of the adverse reactions in these
49 58 Pirker 2009 Phase III NSCLC cisplatin, vinorelbine dyspnea, respiratory failure, 
pulmonary embolism
50 57 Belani 2008 Phase II NSCLC carboplatin, docetaxel none
51 55 Gridelli 2009 Phase II NSCLC gemcitibine pulmonary symptoms
52 59 Shin 2001 Phase I SSCHN Cisplatin Shortness of Breath
53 60 Baselga 2000 Phase I SSCHN/NSCLC Cisplatin Dyspnea
(Abbreviations: SCCHN  squamous cell cancer of the head and neck, NSCLC  non-small cell lung cancer, ExBR  external beam radiation)
Table 1: Studies included in the analysis including first author, year of publication, type of trial and combined therapy, and pulmonary 
adverse reactions. (Continued)Page 4 of 8
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were not noted to be treatment limiting. Although the
mechanism for increased symptoms in patients with
NSCLC is not well defined, it is not surprising that those
with a site of action in the lung would suffer from exuber-
ant local effects. Pneumonitis was seen in most patients
(71%) treated with cetuximab in combination with radia-
tion therapy for NSCLC, although there was no control
group in this study for comparison [56]. These patients
had advanced disease and were treated with a radiation
dose of 64Gy to the lungs, which is well above the thresh-
old for pneumonitis with radiation alone[61] As expected,
treatment of head/neck cancers in these trials had high
overall rates of pulmonary adverse events, although there
were no significant differences between those who
received cetuximab and those who did not.
Severe adverse reactions were not common in clinical tri-
als using cetuximab. Interstitial lung disease, cited as a
rare complication in the medication's package insert, was
not described in the clinical trials included in this review
with the exception of a case report of two post-lung trans-
plantation patients treated with cetuximab for cutaneous
malignancy. Obviously, there are likely confounding fac-
tors which may have predisposed this select population to
the development of diffuse alveolar damage. For those
described in the cetuximab package insert, interstitial lung
disease was present before the institution of cetuximab
therapy for malignancy. Arguably, the increase in pulmo-
nary symptoms in these patients may have been more a
manifestation of ILD progression than as an effect of the
therapeutic. However, the presence of antecedent paren-
chymal lung disease may abrogate the utility of cetuximab
in select patients. Pulmonary embolism, also considered a
severe reaction, occurred in small numbers of patients in
the groups analyzed herein.
An association between the presence of malignancy in the
lung, regardless of primary origin, and pulmonary adverse
events could not be determined from this investigation.
Of the 43 non-lung cancer studies included in our series
only 9 reported the location of metastatic disease. When
combined with studies of lung cancer, 17% of this cohort
reported direct pulmonary involvement of cancer. In
those defining the sites of metastatic foci, the lungs were
involved in 46.0 ± 10% of patients. Primary or metastatic
involvement of the lung with any cancer could account for
patients experiencing pulmonary adverse events when
treated with Cetuximab. Unfortunately, a more clear rela-
tionship is limited by the presentation of the data in the
original studies.
Table 3: Number of patients included by trial type.








n n n n n n
Colorectal 23 3731 2227 76 (3.4) 1367 35 (2.6)
Head-Neck 10 1749 1004 173 (17.2) 516 104 (20.2)
Lung 10 1664 980 189 (19.6) † 671 82 (12.2)
Hepatobiliary/
Pancreatic
5 209 167 9 (5.4) 42 0 (0.0)
Breast/Ovarian 3 78 78 10 (12.8) 0 0 (0.0)
Cutaneous 1 2 2 2 (100) 0 0 (0.0)
TOTAL: 52 7433 4458 459 (10.3) † 2596 221 (8.5)
Patients were grouped into those who received cetuximab, either alone or in combination with other therapeutics, and controls (those who did 
not receive cetuximab). † p < 0.05 compared to control group. * One study contained patients with either Head-Neck or Non-small cell lung 
cancer and is displayed in both groups.
Table 2: Number and type of trials broken into groups according to cancer type.
Trial Type Cancer Type
Colorectal NSCLCa Head-Neck HB-Panc Breast-Ov-Skin TOTAL
Phase I/II 20 9* 10* 5 3 47
Phase III 2 1 1 0 0 4
Case Series/Review 1 0 1 0 1 3
TOTAL 23 10 12 5 4 53
First-Line 5 2 0 0 2 9
Refractory Disease 18 8* 12* 5 2 44
(NSCLCa  nonsmall cell lung cancer, HB-Panc  hepatobiliary or pancreatic, Breast-Ov-Skin  Breast or Ovarian or Cutaneous). * One study 
contained patients with either Head-Neck or Non-small cell lung cancer and is displayed in both groups.Page 5 of 8
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should be pointed out. First, it is a compilation of clinical
trials, most of which are early phase, with limited num-
bers including control populations available for compari-
son of pulmonary adverse events. Most of the studies
examined only cited positive adverse events, omitting
negative responses to pulmonary symptom changes. This
may lead to an over-estimation of the absolute incidence
of pulmonary-specific complications. Conversely, transfu-
sion reactions and sepsis which often include symptoms
such as dyspnea or respiratory insufficiency were not
included in the present analysis due to lack of a clear def-
inition. There were significant differences in the duration
of Cetuximab therapy before pulmonary complications
were reported in the clinical trials, ranging from 1 week
into therapy to more than several months. This also limits
the generalizability of the summation data. Finally,
although there appears to be an increase in the incidence
of pulmonary adverse events with cetuximab therapy,
there is no clearly defined causal relationship that can be
proven as mechanistic understandings are lacking.
Despite these limitations, we believe that this investiga-
tion adds to the sparse literature describing the pulmo-
nary adverse events related to cetuximab therapy.
Conclusion
Cetuximab (Erbitux® ImClone, Branchburg, NJ) therapy,
in combination or as monotherapy, is efficacious in the
treatment of colorectal, head/neck, lung and possibly
other cancers. Although there is an overall increase in the
incidence of pulmonary adverse events with this treat-
ment, there seems to be sparse evidence suggesting treat-
ment limitations related to these complications.
Particular attention should be given to cetuximab recipi-
ents with underlying parenchymal lung disease and those
with NSCLC, in particular in conjunction with radiation
therapy, as these groups may have more severe pulmonary
reactions.
Abbreviations
ILD: Interstitial lung disease; NSCLC: Non-small cell lung
cancer; SCCHN: Squamous cell cancer/head and neck.
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